Clinical Report: Incidental Prostatic Uptake on PET/CT: A Systematic Review
Overview
This systematic review and meta-analysis estimate the prevalence and malignancy risk of incidental prostatic uptake (PIU) on PET/CT scans. The pooled prevalence of PIU was found to be 1.7% for [18F]FDG PET/CT, with a malignancy rate of 21.3% among cases that underwent further evaluation.
Background
Incidental findings on imaging, particularly in the prostate, have become more common with the increased use of PET/CT. Understanding the prevalence and associated malignancy risk of prostatic incidental uptake is crucial for clinicians managing patients with these findings.
Data Highlights
Parameter
Value
Pooled Prevalence of PIU ([18F]FDG)
1.7%
Pooled Prevalence of PIU (SSA)
4.5%
Pooled Malignancy Rate (further evaluation)
21.3%
Pooled Malignancy Rate (biopsy)
59.7%
Key Findings
The pooled prevalence of PIU on [18F]FDG PET/CT is 1.7%.
The prevalence of PIU in SSA PET/CT studies is 4.5%.
The malignancy rate for PIU cases that underwent further evaluation is 21.3%.
For cases that underwent biopsy, the malignancy rate is 59.7%.
Malignant PIUs are associated with higher mean age and higher mean SUVmax compared to benign PIUs.
A peripheral location of PIU is a predictor of malignancy.
Clinical Implications
Individualized clinical correlation is recommended, particularly in the context of elevated PSA levels or other suspicious findings.
Conclusion
PIU is detected in approximately 1.7% of [18F]FDG PET/CT scans in men and is associated with a relevant risk of malignancy.
